Koo Foundation Sun Yat-Sen Cancer Center

Beitou 112

0 studies enrolling now · 2 studies all time

What they study most

Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) — Running, not enrolling